Trial Profile
Phase II study of rituximab (Rituxan, Mabthera) in Waldenstrom's macroglobulinaemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Mar 2010 Actual end date (Jul 2005) and actual number of patients (8) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Oct 2005 New trial record.